Cover Image
市場調查報告書

Meiji Seika Pharma Co., Ltd.的產品平台分析

Meiji Seika Pharma Co., Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321331
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
Meiji Seika Pharma Co., Ltd.的產品平台分析 Meiji Seika Pharma Co., Ltd. - Product Pipeline Review - 2015
出版日期: 2015年12月23日 內容資訊: 英文 51 Pages
簡介

Meiji Seika Pharma是總公司設置於日本的製藥企業,除了進行以抗菌劑等產品為中心的醫療用醫藥品之藥物研發,開發,製造,銷售以外,更製造銷售農業化學產品,動物用醫藥品等產品。

本報告提供Meiji Seika Pharma 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Meiji Seika Pharma 基本資料

  • Meiji Seika Pharma 概要
  • 主要資訊
  • 企業資料

Meiji Seika Pharma :R&D概要

  • 主要的治療範圍

Meiji Seika Pharma :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Meiji Seika Pharma :開發中產品概況

  • 後期階段產品開發中產品
    • 申請登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Meiji Seika Pharma :藥物簡介

  • talaporfin sodium
  • asenapine maleate
  • fluvoxamine maleate
  • ME-1111
  • mirtazapine
  • udenafil
  • ziprasidone hydrochloride
  • arbekacin
  • OP-0595
  • safinamide
  • trastuzumab biosimilar
  • CP-9531

Meiji Seika Pharma :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Meiji Seika Pharma :最新的開發平台資訊

Meiji Seika Pharma :暫停開發的產品

Meiji Seika Pharma :開發中止的開發中產品

  • 開發中止的開發中產品
    • AM-831
    • ME-3738

Meiji Seika Pharma :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07904CDB

Summary

Global Markets Direct's, 'Meiji Seika Pharma Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Meiji Seika Pharma Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Meiji Seika Pharma Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Meiji Seika Pharma Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Meiji Seika Pharma Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Meiji Seika Pharma Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Meiji Seika Pharma Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Meiji Seika Pharma Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Meiji Seika Pharma Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Meiji Seika Pharma Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Meiji Seika Pharma Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Meiji Seika Pharma Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Meiji Seika Pharma Co., Ltd. Snapshot
    • Meiji Seika Pharma Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Meiji Seika Pharma Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Meiji Seika Pharma Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Meiji Seika Pharma Co., Ltd. - Pipeline Products Glance
    • Meiji Seika Pharma Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Meiji Seika Pharma Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Meiji Seika Pharma Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Meiji Seika Pharma Co., Ltd. - Drug Profiles
    • asenapine maleate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fluvoxamine maleate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ziprasidone mesylate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • safinamide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ME-1111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mirtazapine ODT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • talaporfin sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • udenafil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • arbekacin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CP-9531
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Meiji Seika Pharma Co., Ltd. - Pipeline Analysis
    • Meiji Seika Pharma Co., Ltd. - Pipeline Products by Target
    • Meiji Seika Pharma Co., Ltd. - Pipeline Products by Route of Administration
    • Meiji Seika Pharma Co., Ltd. - Pipeline Products by Molecule Type
    • Meiji Seika Pharma Co., Ltd. - Pipeline Products by Mechanism of Action
  • Meiji Seika Pharma Co., Ltd. - Recent Pipeline Updates
  • Meiji Seika Pharma Co., Ltd. - Dormant Projects
  • Meiji Seika Pharma Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • AM-831
      • ME-3738
  • Meiji Seika Pharma Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Meiji Seika Pharma Co., Ltd., Key Information
  • Meiji Seika Pharma Co., Ltd., Key Facts
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Indication, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Stage of Development, 2015
  • Meiji Seika Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Meiji Seika Pharma Co., Ltd. - Partnered Products in Pipeline, 2015
  • Meiji Seika Pharma Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Meiji Seika Pharma Co., Ltd. - Out-Licensed Products in Pipeline, 2015
  • Meiji Seika Pharma Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Meiji Seika Pharma Co., Ltd. - Pre-Registration, 2015
  • Meiji Seika Pharma Co., Ltd. - Phase III, 2015
  • Meiji Seika Pharma Co., Ltd. - Phase II, 2015
  • Meiji Seika Pharma Co., Ltd. - Phase I, 2015
  • Meiji Seika Pharma Co., Ltd. - Preclinical, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Target, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Route of Administration, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Molecule Type, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Meiji Seika Pharma Co., Ltd. - Recent Pipeline Updates, 2015
  • Meiji Seika Pharma Co., Ltd. - Dormant Developmental Projects,2015
  • Meiji Seika Pharma Co., Ltd. - Discontinued Pipeline Products, 2015
  • Meiji Seika Pharma Co., Ltd., Subsidiaries

List of Figures

  • Meiji Seika Pharma Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Stage of Development, 2015
  • Meiji Seika Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Meiji Seika Pharma Co., Ltd. - Partnered Products in Pipeline, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Meiji Seika Pharma Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top